Sean Maduck - 01 Jul 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
01 Jul 2025
Net transactions value
-$14,022
Form type
4
Filing time
03 Jul 2025, 20:35:29 UTC
Previous filing
05 Aug 2025
Next filing
21 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Maduck Sean Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 03 Jul 2025 0001698310

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $1,035 +205 +1.2% $5.05 17,910 01 Jul 2025 Direct F1
transaction CORT Common Stock Sale $15,058 -205 -1.1% $73.45 17,705 01 Jul 2025 Direct F1, F2, F3
holding CORT Common Stock 89,693 01 Jul 2025 See Footnote F4
holding CORT Common Stock 10,000 01 Jul 2025 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -205 -0.33% $0.000000 61,781 01 Jul 2025 Common Stock 205 $5.05 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.40 to $73.62 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F5 Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F6 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.